Shots:
- Xbrane and Intas have entered into a global licensing and co-development agreement for Xbrane’s biosimilar of Opdivo (nivolumab). Intas, through its Accord Healthcare, will commercialize the biosimilar, leveraging its oncology expertise and significant market presence in the EU
- As per the agreement, Intas will fund and manage clinical as well as regulatory development, and lead the commercialization of the nivolumab biosimilar across the globe. The product is expected to launch in the US by Dec 2028 and in the EU after Jun 2030, following patent expirations
- Xbrane is eligible to receive ~$10.58M (EUR 10M) upfront, ~$3.17M (EUR 3M) development milestones and double-digit royalties on profits
Ref: Xbrane Biopharma & Intas Pharmaceuticals | Image: Xbrane Biopharma & Intas Pharmaceuticals | Press Release
Related News:- Fresenius Kabi and Formycon Report the CHMP’s Positive Opinion of Ahzantive/Baiama/FYB203 (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
